You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和鉑醫藥-B(02142.HK): 針對哮喘的抗TSLP全人源單克隆抗體獲批IND許可

格隆匯2月21日丨和鉑醫藥-B(02142.HK)發佈公吿,中國國家藥品監督管理局已批准公司有關HBM9378(或SKB378,由科倫藥業(002422.SZ)附屬公司及公司開發HBM9378的合作伙伴)所述),一款針對胸腺基質淋巴細胞生成素(TSLP)的全人源抗體,用於治療中重度哮喘的研究性新藥(“IND”)申請。

HBM9378/SKB378乃公司與科倫博泰開展的共同開發項目,二者共同享有HBM9378的全球權利。HBM9378獲批IND許可是雙方戰略合作的成果。根據公司與科倫博泰之間的戰略協作及許可協議,雙方將共同探索單克隆抗體創新療法以及抗體偶聯物。

公吿表示,憑藉公司高效的研發平台,以其創新的業務模式為基礎,引領下一代具價值的創新療法以紓解未獲充分滿足的醫療需求為目標,公司將繼續擴大與行業領先合作伙伴的合作,並進一步利用公司與其合作伙伴的綜合能力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account